{"id":997,"date":"2000-05-01T12:05:00","date_gmt":"2000-05-01T10:05:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2000\/beguenstigen-bestimmte-antihypertensiva-die-entwicklung-eines-diabetes-mellitus-typ-2-die-aric-studie"},"modified":"2000-05-01T12:05:00","modified_gmt":"2000-05-01T10:05:00","slug":"beguenstigen-bestimmte-antihypertensiva-die-entwicklung-eines-diabetes-mellitus-typ-2-die-aric-studie","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2000\/beguenstigen-bestimmte-antihypertensiva-die-entwicklung-eines-diabetes-mellitus-typ-2-die-aric-studie","title":{"rendered":"Beg\u00fcnstigen bestimmte Antihypertensiva die Entwicklung eines Diabetes mellitus Typ 2? Die ARIC-Studie"},"content":{"rendered":"<p>Diese Frage stellten sich die Autoren der ARIC-Studie, die auf der Auswertung einer umfangreichen Datenerhebung \u00fcber Risikofaktoren f\u00fcr Arteriosklerose beruht (Gress, T.W., et al. for the Atherosclerotic Risk In Communities Study: N. Engl. J. Med. 2000, 342, 905). Die Daten wurden in verschiedenen Staaten oder Counties der USA gesammelt. Die Rekrutierung der prospektiv zu untersuchenden [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Diese Frage stellten sich die Autoren der ARIC-Studie, die auf der Auswertung einer umfangreichen Datenerhebung \u00fcber Risikofaktoren f\u00fcr Arteriosklerose beruht (Gress, T.W., et al. for the Atherosclerotic Risk In Communities Study: N. Engl. J. Med. 2000, 342, 905). Die Daten wurden in verschiedenen Staaten oder Counties der USA gesammelt. Die Rekrutierung der prospektiv zu untersuchenden [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[130,2517,129,128,131,155,134,437],"class_list":["post-997","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-ace-hemmer","tag-aric-studie","tag-beta-blocker","tag-betablocker","tag-betarezeptoren-blocker","tag-diabetes-mellitus-typ-2","tag-kalziumantagonisten","tag-thiazide"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/997","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=997"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/997\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=997"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=997"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=997"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}